A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment¹

详细信息    查看全文

• 作者：Tian C. Zhou ; M.D.^a ; ^{tianc.zhou@gmail.com} ; Alexander I. Sankin ; M.D.^a ; Steven A. Porcelli ; M.D.^b ; ^c ; David S. Perlin ; Ph.D.^d ; Mark P. Schoenberg ; M.D.^a ; Xingxing Zang ; Ph.D.^b ; ^c
• 关键词：PD-1 ; PD-L1 ; Bladder cancer ; BCG failure ; Immunotherapy ; Biomarker
• 刊名：Urologic Oncology: Seminars and Original Investigations
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：35
• 期：1
• 页码：14-20
• 全文大小：407 K
• 卷排序：35

文摘

PD-1/PD-L1 pathway may be manipulated by cancer cells to subvert the immune system. Anti-PD-L1 antibody atezolizumab is approved for metastatic urothelial carcinoma. Immunohistochemistry limits the use of PD-L1 as a prognostic biomarker.